North America Molecular Diagnostics for Infectious Disease Market Forecast to 2030 - Regional Analysis - by Type (Point-of-Care Testing and Laboratory Testing), End User, Application, Disease Type, Infection Type

Description

List of Tables

The North America molecular diagnostics for infectious disease market was valued at US$ 3,345.15 million in 2022 and is expected to reach US$ 8,419.70 million by 2030; it is estimated to grow at a CAGR of 12.2% from 2022 to 2030.

Molecular Diagnostics for Infectious Diseases in Personalized Medicine Fuels the North America Molecular Diagnostics for Infectious Disease Market

Genome research has become more convenient and cost-effective with progress in high-throughput techniques. Molecular diagnostics is becoming increasingly indispensable in clinical laboratories as these kits and tests provide rapid detection results as opposed to conventional tests, which involve culturing microbes in laboratory conditions in a few cases. Medical treatments and interventions are tailored to each patient using precision medicine based on their unique genetic makeup, lifestyle, and environment. Molecular diagnostics plays an important role in this approach, as it enables the identification of specific biomarkers, genetic mutations, and gene expression patterns that impact decision-making related to the treatment of patients. Drug development has become increasingly dependent on molecular diagnostics. Various molecular imaging techniques are used in screening, detecting, diagnosing, treating, and assessing heterogeneity to make progression plans, examine molecular characteristics, and monitor patient outcomes. Personalized medicine generally aims to interrogate the genomic information of a patient, e.g., drug metabolism polymorphisms help guide drug choice and dosage. In infectious diseases, personalized medicine concepts can be used to rapidly identify disease-causing microorganisms, determine their antimicrobial resistance profiles, and ascertain an appropriate antimicrobial treatment for the proper management of the patient based on the results. Point-of-care testing for infectious diseases requires the acceptance of medical authorities, development of new technology and communication platforms, and reimbursement policies so that the greatest number of patients can benefit from lifesaving and time-saving procedures. Introducing these techniques into clinical practice would enable the identification of molecular targets in each patient, along with facilitating the tracking of the molecular progression of diseases.

Thus, with ever-evolving technology, the market for molecular diagnostics for infectious diseases seems to have a bright future.

North America Molecular Diagnostics for Infectious Disease Market Overview

The increasing prevalence of tuberculosis (TB) and rise in awareness of diagnosis and treatment for TB in Mexico is fueling the growth of the molecular diagnosis for infectious diseases market. According to StopTB Partnership Organization, the number of people suffering from TB rose from 30,000 in 2019 to 31,000 in 2020. The growing focus of Centers for Disease Control and Prevention (CDC) has established several international laboratory projects in Mexico. These projects include two projects for the detection of drug-sensitive and drug-resistant TB cases in Sonora and Baja California, Mexico. The common goal of these two projects is to build capacity for state and national disease control program to identify the group at risk and conduct rapid TB tests on that group. These initiatives for screening the masses for TB are creating awareness in the Mexican population. In addition, the extensively growing pharmaceuticals industry, developing healthcare infrastructure, and elevating demand for diagnostic testing products bolster the molecular diagnostics for infectious diseases market growth in Mexico. In February 2021, the World Health Organization (WHO) announced significant advancements in the diagnosis of TB and drug resistance in children, adolescents, and adults. The three new classes of technologies announced for testing TB were as follows:

Moderate-complexity automated Nucleic Acid Amplification Tests (NAATs) for the diagnosis of TB and detection of variants resistant to rifampicin and isoniazid
Low-complexity automated NAATs for detection of resistance to isoniazid and second-line anti-TB agents
High-complexity hybridization-based NAATs for the detection of resistance to pyrazinamide.

North America Molecular Diagnostics for Infectious Disease Market Revenue and Forecast to 2030 (US$ Million)

North America Molecular Diagnostics for Infectious Disease Market Segmentation

The North America molecular diagnostics for infectious disease market is segmented based on type, end user, application, disease type, infection type, and country.

Based on type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The laboratory testing segment held a larger North America molecular diagnostics market for infectious disease market share in 2022.

The North America molecular diagnostics for infectious disease market, by end user, is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further bifurcated into human testing and vet testing. Similarly, laboratory testing is further bifurcated into human testing and vet testing. The human testing segment, by point-of-care testing, held a larger North America molecular diagnostics market for infectious disease market share in 2022. Additionally, the human testing segment, by laboratory testing, held a larger North America molecular diagnostics market for infectious disease market share in 2022.

Based on application, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into detection of single pathogen, detection of two or more pathogens, evaluation of emerging novel infections, surveillance and early detection of biothreat agents and diseases-related biomarker, and antimicrobial resistance profiling. Similarly, laboratory testing is further categorized into patient stratification, drug regimen selection, toxicity avoidance, therapeutic monitoring, and detection of predisposition to disease. The detection of a single pathogen segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the drug regimen selection segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.

Based on disease type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. Point-of-care testing is further segmented into sepsis (e.g. urogenital/lung/wound), prosthetic joint infection, endocarditis, STDs, mononucleosis, group A streptococcus, and others. Similarly, laboratory testing is further categorized into sepsis, prosthetic joint infection, endocarditis, STDs, chlamydia, gastrointestinal infection, tuberculosis, H1N1 virus, and others. The STDs segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the STDs segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.

Based on infection type, the North America molecular diagnostics for infectious disease market is bifurcated into point-of-care testing and laboratory testing. The point-of-care testing is further segmented into bacteria, viral, fungi, and others. Similarly, laboratory testing is further categorized into bacteria, viral, fungi, and others. The bacteria segment, by point-of-care testing, held the largest North America molecular diagnostics for infectious disease market share in 2022. Additionally, the bacteria segment, by laboratory testing, held the largest North America molecular diagnostics for infectious disease market share in 2022.

Based on country, the North America molecular diagnostics for infectious disease market is categorized into the US, Canada, and Mexico. The US dominated the North America molecular diagnostics for infectious disease market in 2022.

Abbott Laboratories, bioMerieux SA, Bruker Corp, Danaher Corp, DiaSorin SpA, F. Hoffmann-La Roche Ltd, Hologic Inc, Siemens Healthineers AG, and Thermo Fisher Scientific Inc are some of the leading companies operating in the North America molecular diagnostics for infectious disease market.

Product Code: BMIRE00029839

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 North America Molecular Diagnostic for Infectious Diseases Market, by Country, Market attractiveness

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. North America Molecular Diagnostic for Infectious Diseases Market - Key Industry Dynamics

4.1 Market Drivers:
- 4.1.1 Surging Prevalence of Infectious Disease Globally
- 4.1.2 Rising Application of Molecular Diagnostics in Veterinary Infectious Diseases
4.2 Market Restraints
- 4.2.1 Limitations Associated with Molecular Testing
4.3 Market Opportunities
- 4.3.1 Advancements in Molecular Diagnostics Technologies
4.4 Future Trends
- 4.4.1 Molecular Diagnostics for Infectious Diseases in Personalized Medicine
4.5 Impact Analysis:

5. Molecular Diagnostic for Infectious Diseases Market - North America Market Analysis

5.1 North America Molecular Diagnostic for Infectious Diseases Market Revenue (US$ Mn), 2022 - 2030

6. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Type

6.1 Overview
6.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, by Type, 2022 & 2030 (%)
6.3 Point-of-Care Testing
- 6.3.1 Overview
- 6.3.2 Point-of-Care Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Laboratory Testing
- 6.4.1 Overview
- 6.4.2 Laboratory Testing: North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 (US$ Million)

7. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by End User

7.1 Overview
7.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing and Laboratory Testing by End User, 2022 & 2030 (%)
- 7.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
- 7.2.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)

8. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Application

8.1 Overview
8.2 Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Application, 2022 & 2030 (%)
8.3 Point-of-Care Testing
- 8.3.1 Overview
- 8.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
8.4 Laboratory Testing
- 8.4.1 Overview
- 8.4.2 North America: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)

9. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Disease Type

9.1 Overview
9.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Disease Type, 2022 & 2030 (%)
9.3 Point-of-Care Testing
- 9.3.1 Overview
- 9.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
  - 9.3.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
9.4 Laboratory Testing
- 9.4.1 Overview
- 9.4.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
  - 9.4.2.1 North America Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)

10. North America Molecular Diagnostic for Infectious Diseases Market - Revenue and Forecast to 2030 - by Infection Type

10.1 Overview
10.2 North America Molecular Diagnostic for Infectious Diseases Market Revenue Share, For Point-of-Care Testing by Infection Type, 2022 & 2030 (%)
10.3 Point-of-Care Testing
- 10.3.1 Overview
- 10.3.2 North America Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
10.4 Laboratory Testing
- 10.4.1 Overview
- 10.4.2 North America Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)

11. North America Molecular Diagnostic for Infectious Diseases Market - Country Analysis

11.1 North America Molecular Diagnostic for Infectious Diseases Market, Revenue and Forecast To 2030
- 11.1.1 Overview
- 11.1.2 North America Molecular Diagnostic for Infectious Diseases Market, by Country
  - 11.1.2.1 US
    - 11.1.2.1.1 US Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.1.2 US: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.1.3 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.1.4 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.1.5 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.1.6 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.1.7 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.1.7.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.1.8 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.1.8.1 US: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.1.9 US: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.1.10 US: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.2 Canada
    - 11.1.2.2.1 Canada Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.2.2 Canada: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.2.3 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.2.4 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.2.5 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.2.6 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.2.7 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.2.7.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.2.8 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.2.8.1 Canada: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.2.9 Canada: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.2.10 Canada: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)
  - 11.1.2.3 Mexico
    - 11.1.2.3.1 Mexico Molecular Diagnostic for Infectious Diseases Market Revenue and Forecast to 2030 (US$ Mn)
    - 11.1.2.3.2 Mexico: Molecular Diagnostic for Infectious Diseases Market, by Type, 2020-2030 (US$ Million)
    - 11.1.2.3.3 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.3.4 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by End User, 2020-2030 (US$ Million)
    - 11.1.2.3.5 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.3.6 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Application, 2020-2030 (US$ Million)
    - 11.1.2.3.7 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.3.7.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Point-of-Care Testing, 2020-2030 (US$ Million)
    - 11.1.2.3.8 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Disease Type, 2020-2030 (US$ Million)
    - 11.1.2.3.8.1 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Sepsis by Laboratory Testing, 2020-2030 (US$ Million)
    - 11.1.2.3.9 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Point-of-Care Testing by Infection Type, 2020-2030 (US$ Million)
    - 11.1.2.3.10 Mexico: Molecular Diagnostic for Infectious Diseases Market, for Laboratory Testing by Infection Type, 2020-2030 (US$ Million)

12. Industry Landscape

12.1 Overview
12.2 Growth Strategies Done by the Companies in the Market, (%)
12.3 Organic Developments
- 12.3.1 Overview
12.4 Inorganic Developments
- 12.4.1 Overview

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Abbott Laboratories
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Thermo Fisher Scientific Inc
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 bioMerieux SA
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Danaher Corp
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Hologic Inc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Siemens Healthineers AG
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Bruker Corp
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 DiaSorin SpA
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments

14. Appendix

14.1 About Us
14.2 Glossary of Terms